Stephen B Freedman1, Mohamed Eltorki2, Linda Chui3, Jianling Xie4, Sharon Feng5, Judy MacDonald6, Andrew Dixon7, Samina Ali7, Marie Louie8, Bonita E Lee7, Lara Osterreicher9, Jennifer Thull-Freedman4. 1. Sections of Pediatric Emergency Medicine and Gastroenterology, Department of Pediatrics, Alberta Children's Hospital, Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada. Electronic address: stephen.freedman@albertahealthservices.ca. 2. Division of Pediatric Emergency Medicine, McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada. 3. Provincial Laboratory for Public Health, Edmonton, Alberta, Canada; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada. 4. Section of Pediatric Emergency Medicine, Alberta Children's Hospital, Department of Pediatrics, Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada. 5. Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada. 6. Population, Public and Indigenous Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 7. Department of Pediatrics, Faculty of Medicine & Dentistry, Women and Children's Health Research Institute, University of Alberta, Edmonton, Alberta. 8. Provincial Laboratory for Public Health, Edmonton, Alberta, Canada; Department of Microbiology Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada. 9. Provincial Clinical Programs, Health Link, Alberta Health Services, Edmonton, Alberta, Canada.
Abstract
OBJECTIVE: To identify the gaps in the care of children infected with Shiga toxin-producing Escherichia coli (STEC), we sought to quantitate care received and management timelines. Such knowledge is crucial to the design of interventions to prevent the development of hemolytic uremic syndrome (HUS). STUDY DESIGN: We conducted a retrospective case-series study of 78 children infected with STEC in Alberta, Canada, through the linkage of microbiology and laboratory results, telephone health advice records, hospital charts, physician billing submissions, and outpatient antimicrobial dispensing databases. Outcomes were the time intervals between initial presentation and reporting of positive culture result and symptom onset to HUS and to describe the proportions that had baseline blood work performed and received antibiotics. RESULTS: Seventy-eight children infected with STEC were identified; 13% (10/78) developed HUS. Median time from initial presentation to laboratory stool sample receipt was 33 hours (IQR 18, 42); time to positive culture was 120 hours (IQR 86, 205). Time from symptom onset to HUS diagnosis was 188 ± 37 hours. Baseline blood tests were obtained in 74% (58/78) of infected children. Antibiotics were administered to 50% (5/10) of those who developed HUS and 22% (15/78) of those who did not; P = .11. The provincial telephone advice system received 31 calls regarding 24 children infected with STEC; 23% (7/31) of callers were recommended to seek emergency department care. CONCLUSIONS: A significant proportion of children developed HUS following multiple interactions with the health care system. Delays in the confirmation of STEC infection occurred. There are numerous opportunities to improve the timing, monitoring, and interventions in children infected with STEC.
OBJECTIVE: To identify the gaps in the care of children infected with Shiga toxin-producing Escherichia coli (STEC), we sought to quantitate care received and management timelines. Such knowledge is crucial to the design of interventions to prevent the development of hemolytic uremic syndrome (HUS). STUDY DESIGN: We conducted a retrospective case-series study of 78 children infected with STEC in Alberta, Canada, through the linkage of microbiology and laboratory results, telephone health advice records, hospital charts, physician billing submissions, and outpatient antimicrobial dispensing databases. Outcomes were the time intervals between initial presentation and reporting of positive culture result and symptom onset to HUS and to describe the proportions that had baseline blood work performed and received antibiotics. RESULTS: Seventy-eight children infected with STEC were identified; 13% (10/78) developed HUS. Median time from initial presentation to laboratory stool sample receipt was 33 hours (IQR 18, 42); time to positive culture was 120 hours (IQR 86, 205). Time from symptom onset to HUS diagnosis was 188 ± 37 hours. Baseline blood tests were obtained in 74% (58/78) of infected children. Antibiotics were administered to 50% (5/10) of those who developed HUS and 22% (15/78) of those who did not; P = .11. The provincial telephone advice system received 31 calls regarding 24 children infected with STEC; 23% (7/31) of callers were recommended to seek emergency department care. CONCLUSIONS: A significant proportion of children developed HUS following multiple interactions with the health care system. Delays in the confirmation of STEC infection occurred. There are numerous opportunities to improve the timing, monitoring, and interventions in children infected with STEC.
Authors: Stephen B Freedman; Jianling Xie; Alberto Nettel-Aguirre; Bonita Lee; Linda Chui; Xiao-Li Pang; Ran Zhuo; Brendon Parsons; James A Dickinson; Otto G Vanderkooi; Samina Ali; Lara Osterreicher; Karen Lowerison; Phillip I Tarr Journal: Lancet Gastroenterol Hepatol Date: 2017-07-14
Authors: Jianling Xie; Gillian A M Tarr; Samina Ali; Linda Chui; Xiao-Li Pang; Bonita E Lee; Otto G Vanderkooi; Phillip I Tarr; Ran Zhuo; Brendon Parsons; Byron M Berenger; Kelly Kim; Stephen B Freedman Journal: J Clin Microbiol Date: 2019-05-24 Impact factor: 5.948
Authors: Ryan S McKee; David Schnadower; Phillip I Tarr; Jianling Xie; Yaron Finkelstein; Neil Desai; Roni D Lane; Kelly R Bergmann; Ron L Kaplan; Selena Hariharan; Andrea T Cruz; Daniel M Cohen; Andrew Dixon; Sriram Ramgopal; Annie Rominger; Elizabeth C Powell; Jennifer Kilgar; Kenneth A Michelson; Darcy Beer; Martin Bitzan; Christopher M Pruitt; Kenneth Yen; Garth D Meckler; Amy C Plint; Stuart Bradin; Thomas J Abramo; Serge Gouin; April J Kam; Abigail Schuh; Fran Balamuth; Tracy E Hunley; John T Kanegaye; Nicholas E Jones; Usha Avva; Robert Porter; Daniel M Fein; Jeffrey P Louie; Stephen B Freedman Journal: Clin Infect Dis Date: 2020-04-10 Impact factor: 9.079
Authors: Gillian A M Tarr; Hanna N Oltean; Amanda I Phipps; Peter Rabinowitz; Phillip I Tarr Journal: Int J Med Microbiol Date: 2018-10-10 Impact factor: 3.473
Authors: Celia R Walker; Kwana Lechiile; Margaret Mokomane; Andrew P Steenhoff; Tonya Arscott-Mills; Jeffrey M Pernica; David M Goldfarb Journal: J Clin Microbiol Date: 2019-11-22 Impact factor: 5.948
Authors: Gillian A M Tarr; Hanna N Oltean; Amanda I Phipps; Peter Rabinowitz; Phillip I Tarr Journal: Int J Med Microbiol Date: 2018-06-26 Impact factor: 3.473
Authors: Otto G Vanderkooi; Jianling Xie; Bonita E Lee; Xiao-Li Pang; Linda Chui; Daniel C Payne; Judy MacDonald; Samina Ali; Shannon MacDonald; Steve Drews; Lara Osterreicher; Kelly Kim; Stephen B Freedman Journal: Eur J Clin Microbiol Infect Dis Date: 2019-09-09 Impact factor: 3.267
Authors: Mario Giordano; Maria Elisabetta Baldassarre; Viviana Palmieri; Diletta D Torres; Vincenza Carbone; Luisa Santangelo; Federico Gentile; Raffaella Panza; Federica Di Mauro; Manuela Capozza; Antonio Di Mauro; Nicola Laforgia Journal: Int J Environ Res Public Health Date: 2019-05-12 Impact factor: 3.390
Authors: Ryan S McKee; Phillip I Tarr; Dennis J Dietzen; Rachit Chawla; David Schnadower Journal: J Pediatric Infect Dis Soc Date: 2018-08-17 Impact factor: 3.164
Authors: Luiz F Lisboa; Jonas Szelewicki; Alex Lin; Sarah Latonas; Vincent Li; Shuai Zhi; Brendon D Parsons; Byron Berenger; Sumana Fathima; Linda Chui Journal: Toxins (Basel) Date: 2019-10-22 Impact factor: 4.546